Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
1.
Indian J Dermatol Venereol Leprol ; 85(4): 355-366, 2019.
Artigo em Inglês | MEDLINE | ID: mdl-31172979

RESUMO

BACKGROUND: Present day therapeutic modalities for viral warts are mostly ablative in nature, limited by high recurrence rates and are unsuitable for numerous lesions. Immunotherapy has the potential to overcome these limitations. AIMS: This study aimed at comparing efficacy and safety of and quality of life changes with intradermal purified protein derivative (PPD) of tuberculin antigen and Mycobacterium w (Mw) vaccine in immunotherapy of warts. METHODS: Patients with multiple (≥5) warts were randomized (1:1) into two groups (PPDand, Mw vaccine groups). Fortnightly, 0.1 ml of either medicine was injected intradermally over the deltoidregion till complete resolution or a maximum of six doses. Patients were followed-up for another 3 months for recurrence. RESULTS: Sixty-four participants received either PPD or Mw vaccine. The number of warts were comparable at baseline (P = 0.089, Mann-Whitney test), and reduced significantly with treatment in both groups (P < 0.001, Friedman's ANOVA), as seen from the fourth follow-up onwards with Mw and fifth follow-up onwards with PPD (P < 0.05, Post hoc Dunn's test). Intergroup comparison showed significantly more (P < 0.05, Mann-Whitney test) reduction with Mw than PPD at the sixth and seventh follow-up. The size of warts also reduced significantly (P < 0.001) in both groups from the third follow-up onwards. Complete remission was more (P = 0.539, Fischer's exact test) in the Mw group (68.8%) than the PPD group (50%); and was significantly higher (P = 0.049, Mann-Whitney test) in patients having shorter duration of warts. Adverse events were significantly more (P < 0.001) with Mw including ulceration (50%), discharge (15.6%), pain-swelling-induration and scar at the injection site (97% each), whereas some of those receiving PPD noted erythema and scaling at the injection site (18.8%), and post-inflammatory hyperpigmentation (12.5%). No recurrence was seen till the end of the study. LIMITATION: Unicentric trial. CONCLUSION: Intradermal injection of Mw vaccine was more effective but had a higher incidence of adverse effects compared to PPD of tuberculin antigen in patients with warts.


Assuntos
Vacinas Bacterianas/uso terapêutico , Reação no Local da Injeção/etiologia , Tuberculina/uso terapêutico , Verrugas/terapia , Adolescente , Adulto , Vacinas Bacterianas/efeitos adversos , Método Duplo-Cego , Eritema/induzido quimicamente , Feminino , Seguimentos , Humanos , Hiperpigmentação/induzido quimicamente , Injeções Intradérmicas , Masculino , Dor/induzido quimicamente , Recidiva , Indução de Remissão , Úlcera Cutânea/induzido quimicamente , Tuberculina/efeitos adversos , Adulto Jovem
3.
Rev. bras. leprol ; 23(1/4): 23-40, jan.-dec. 1955. tab
Artigo em Português | SES-SP, HANSEN, HANSENIASE, SESSP-ILSLACERVO, SES-SP | ID: biblio-1229485

RESUMO

There existe no mutual relation between positiveness to Mantoux test and to that of Mitsuda among lepromatous patients. This fact constitutes, just like many others in the field of leprosy, an open question to further investigations.


Assuntos
Antígeno de Mitsuda/biossíntese , Antígeno de Mitsuda/fisiologia , Antígeno de Mitsuda/uso terapêutico , Tuberculina/biossíntese , Tuberculina/fisiologia , Tuberculina/uso terapêutico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA